

- [Investor Presentation](#)
- [Events](#)
- [Earnings Calls & Releases](#)
- [SEC Filings](#)
- [Annual Meeting & Reports](#)
- [Corporate Governance](#)
- [Investor Resources](#)



Cardiology

- [Companies](#)
- [Professional Products](#)
- [Disease Areas](#)
- [Cardiology](#)
- [Drugs of Abuse](#)
- [Infectious Disease](#)
- [Oncology](#)
- [Women's Health](#)
- [Brands](#)
- [Health Management](#)
- [Consumer](#)

[Professional Products](#) [Disease Areas](#)

InRatio®

Over 7 million people worldwide take oral anticoagulants such as Coumadin® to help reduce the body's chances of forming harmful blood clots. The INRatio monitor measures Prothrombin Time (PT)/INR, the critical test performed to maintain the proper "therapeutic range" of oral anticoagulation therapies.

More professionals are using INRatio at the point of care to take advantage of its on board quality controls, non-refrigerated test strips, small sample size, and fast results to care for their patients and make needed dosage adjustments face to face.

Patient self-testing offers the convenience of testing PT/INR levels when and where the patient wants. INRatio's reliability and ease of use has made it a trusted choice for patients who want to test at home.

For more information on INRatio Systems and PT/INR monitoring visit <http://www.hemosense.com/>.

[InRatio® Meter](#)

[InRatio®2 Meter](#)